Many summers ago, I started my career working for a researching pharmaceutical company and learned how we had to recruit researchers to conduct clinical trials (along with the data collection, reimbursements, and incentives), conduct post-market surveillance, launch new products and preparations and so on – and unfortunately, shockingly little has changed in the pharmaceutical industry in the way they conduct business conceptually.
Research from Gartner®, “Innovation Insight for Digital Life Science Platform,” calls for a drastic change in the way Life Science companies structure their IT assets to unlock value in the healthcare data they are collecting. According to Gartner, “Unlocking the value of healthcare data is a top priority for life science organization CIOs as the industry enters an era of consumer engagement, precision medicine and personalized health.”
Gartner mentions that “Life science organizations are increasingly questioning the value delivered by their existing IT investments, such as inflexible and monolithic ERP-centric application suites that can be a barrier to digital innovation and productivity and have a high total cost of ownership (TCO).” Additionally, Gartner recommends that Life Science organization leaders should, “Introduce the digital life science platform (DLSP) approach to your business by making the connection between business-led demands and market disruption and the need for more organizational agility and efficiency, in order to thrive amid these changes.”
So why is a predominantly ERP company like Infor providing complimentary access to the Gartner research report?
Gartner states that one of the transformational steps is “Harnessing the sheer amount of data and forming the connections across both internal and external parties will require new levels of interoperability.”
With Cloverleaf, Infor also has the #1 clinical interoperability platform, and from our perspective an important technology to help in the transformation of life science organizations towards a DLSP.
Our goal is to bridge the interoperability gap between healthcare providers and life science companies to feed the data fabric of the DLSP with real-word data (RWD) for patient-centric workflows and decision making by combining curated data from EHRs with medical and prescription claims, registries, and other episodic and longitudinal clinical data sources.
Gartner provides insights into key features of the DLSP integrated data fabric layer, by stating that it “Enables organizations to leverage real-world data (RWD) to derive actionable insights that inform prelaunch and postlaunch commercial activities, including competitive benchmarking, market sizing and surveillance, segmentation and profiling, sales performance management, and value-based contracting,” further stating that, “Facilitates health data connectors using industry standards such as HL7 and Fast Healthcare Interoperability Resources (FHIR), and support for some proprietary or more basic forms of integration to extract and exchange data (e.g., supporting batch transfer or EHR overnight data extracts used to update proprietary EHR BI tools).”
The benefit of HL7 FHIR is that is much more suited for data aggregation and analytics compared to legacy healthcare standards, and therefore the goal of a tighter link between healthcare research and delivery can be fulfilled for the first time. Not only can HL7 FHIR store all the RWD in a lossless format, but there are also plenty of tools available to map these FHIR resources into specific life science research data formats such as OMOP or CDISC at various levels of pseudonymization and deidentification.
Please click this link to read the full Gartner research report, and please contact us to discuss how we can help you in your DLSP implementation.
--
Gartner, Innovation Insight for Digital Life Science Platforms, Michael Shanler, Rohan Sinha, Animesh Gandhi, Jeff Smith, Refreshed 21 March 2023, Published 12 October 2021. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Let's Connect
Contact us and we'll have a Business Development Representative contact you within 24 business hours.